JP2023512821A5 - - Google Patents

Info

Publication number
JP2023512821A5
JP2023512821A5 JP2022548039A JP2022548039A JP2023512821A5 JP 2023512821 A5 JP2023512821 A5 JP 2023512821A5 JP 2022548039 A JP2022548039 A JP 2022548039A JP 2022548039 A JP2022548039 A JP 2022548039A JP 2023512821 A5 JP2023512821 A5 JP 2023512821A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
hydrogen
alkylene
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022548039A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023512821A (ja
JP7824222B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2021/050122 external-priority patent/WO2021155467A1/en
Publication of JP2023512821A publication Critical patent/JP2023512821A/ja
Publication of JP2023512821A5 publication Critical patent/JP2023512821A5/ja
Priority to JP2025279101A priority Critical patent/JP2026053548A/ja
Application granted granted Critical
Publication of JP7824222B2 publication Critical patent/JP7824222B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022548039A 2020-02-04 2021-02-04 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体 Active JP7824222B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025279101A JP2026053548A (ja) 2020-02-04 2025-12-23 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062969894P 2020-02-04 2020-02-04
US62/969,894 2020-02-04
PCT/CA2021/050122 WO2021155467A1 (en) 2020-02-04 2021-02-04 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025279101A Division JP2026053548A (ja) 2020-02-04 2025-12-23 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体

Publications (3)

Publication Number Publication Date
JP2023512821A JP2023512821A (ja) 2023-03-29
JP2023512821A5 true JP2023512821A5 (cg-RX-API-DMAC7.html) 2024-02-13
JP7824222B2 JP7824222B2 (ja) 2026-03-04

Family

ID=77199114

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548039A Active JP7824222B2 (ja) 2020-02-04 2021-02-04 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体
JP2025279101A Pending JP2026053548A (ja) 2020-02-04 2025-12-23 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025279101A Pending JP2026053548A (ja) 2020-02-04 2025-12-23 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としての3-ピロリジンインドール誘導体

Country Status (11)

Country Link
US (3) US11453689B2 (cg-RX-API-DMAC7.html)
EP (1) EP4100403A4 (cg-RX-API-DMAC7.html)
JP (2) JP7824222B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220137085A (cg-RX-API-DMAC7.html)
CN (1) CN115380028A (cg-RX-API-DMAC7.html)
AU (1) AU2021215709A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015379A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166940A1 (cg-RX-API-DMAC7.html)
IL (1) IL295374A (cg-RX-API-DMAC7.html)
MX (1) MX2022009528A (cg-RX-API-DMAC7.html)
WO (1) WO2021155467A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021215709A1 (en) * 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
MX2023010317A (es) * 2021-03-02 2023-11-09 Mindset Pharma Inc Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos.
WO2022246572A1 (en) * 2021-05-26 2022-12-01 Mindset Pharma Inc. Hallucinogen-fatty acid combination
KR20240017363A (ko) * 2021-06-02 2024-02-07 세인트 조셉스 유니버시티 플루오린화 트립타민 화합물, 이의 유사체 및 이를 사용하는 방법
CA3229361A1 (en) * 2021-08-20 2023-02-23 Abdelmalik Slassi 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
CA3243296A1 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. PSYCHEDELIC COMPOUNDS AND THEIR THERAPEUTIC USES
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
JP2025513461A (ja) * 2022-04-19 2025-04-24 マインドセット ファーマ インコーポレイテッド セロトニン作動薬としてのインドリン誘導体に関連する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体
CN117586171A (zh) * 2022-08-12 2024-02-23 长春金赛药业有限责任公司 吲哚类衍生物、药物组合物及其在中枢神经领域的应用
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
WO2025104491A1 (en) 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
TW202619712A (zh) * 2024-09-09 2026-05-16 大陸商翼思生物醫藥(蘇州)有限公司 5-ht2a受體激動劑及m4活化劑之組合及其用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
TW288010B (cg-RX-API-DMAC7.html) * 1992-03-05 1996-10-11 Pfizer
AU670579B2 (en) * 1992-04-07 1996-07-25 Pfizer Inc. Indole derivatives as 5-HT1 agonists
KR960701865A (ko) * 1993-04-22 1996-03-28 데이비드 존. 우드 편두통에 사용하는 5-HT1 유사 효능제인 인돌 유도체(Indole Derivatives as 5-HT, -Like Agonists for Use in Migraine)
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
JP2001503414A (ja) 1996-10-31 2001-03-13 ハーバー ブランチ オーシャノグラフィック インスティテューション インク. 抗神経性炎症化合物および組成物ならびにその使用法
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9816263D0 (en) 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
US6841685B2 (en) 2000-06-07 2005-01-11 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for making bis-heterocyclic alkaloids
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
WO2005062985A2 (en) * 2003-12-23 2005-07-14 American Bioscience, Inc. Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
MX2007003375A (es) 2004-09-22 2007-05-07 Janssen Pharmaceutica Nv Inhibidores de la interaccion entre mdm2 y p53.
ATE489138T1 (de) 2005-04-13 2010-12-15 Neuraxon Inc Substituierte indolverbindungen mit nos-hemmender aktivität
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
DK1981875T3 (da) 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
EP2029136A4 (en) * 2006-05-22 2010-01-06 Vanda Pharmaceuticals Inc TREATMENT FOR DEPRESSION DISEASES
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
WO2008036967A2 (en) 2006-09-22 2008-03-27 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds as lasy activators
US20090014868A1 (en) 2007-07-10 2009-01-15 International Business Machines Corporation Manufacturing ic chip in portions for later combining, and related structure
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
WO2010132072A1 (en) 2009-05-15 2010-11-18 Neuraxon, Inc Treatment or prevention of migraine by dosing at aura
EP2668177B1 (en) 2011-01-28 2014-10-22 Boehringer Ingelheim International GmbH Substituted pyridinyl-pyrimidines and their use as medicaments
HUE039750T2 (hu) * 2014-06-26 2019-02-28 Contera Pharma Aps Hidroxi-buspiron mozgászavarok kezelésére
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
WO2017042643A1 (en) * 2015-09-10 2017-03-16 Suven Life Sciences Limited Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
WO2018094106A2 (en) 2016-11-16 2018-05-24 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
CA3077053A1 (en) * 2017-09-27 2019-04-04 Ohio State Innovation Foundation Methods and compositions for inhibition of stat3
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
MX2021009037A (es) 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
US12616706B2 (en) 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
US20230021957A1 (en) 2019-12-04 2023-01-26 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
AU2021215709A1 (en) * 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
US20210236523A1 (en) 2020-02-05 2021-08-05 Yale University Psychedelic treatment for headache disorders
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2021116503A2 (en) 2020-06-02 2021-06-17 Small Pharma Ltd Deuterated compounds
DK4172145T3 (da) 2020-06-30 2026-07-20 Reunion Neuroscience Inc Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
WO2022018709A1 (en) 2020-07-21 2022-01-27 Ai Pharmaceuticals Jamaica Limited Compositions and methods for treatment of psychoses and psychotic disorders
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Similar Documents

Publication Publication Date Title
JP2023513679A5 (cg-RX-API-DMAC7.html)
JP2023553094A5 (cg-RX-API-DMAC7.html)
IL295371A (en) Psilocyin derivatives as serotonergic psychedelics for the treatment of central nervous system disorders
JP2024508922A5 (cg-RX-API-DMAC7.html)
JP2023513680A5 (cg-RX-API-DMAC7.html)
JP5586577B2 (ja) 架橋複素環化合物およびその使用
JP2024508545A5 (cg-RX-API-DMAC7.html)
JP6933964B2 (ja) ヘテロアリール化合物およびそれらの使用方法
JP2025501629A5 (cg-RX-API-DMAC7.html)
JP2017502073A (ja) 置換ベンゾオキサジン及び関連化合物
AR059016A4 (es) Derivados de aril-isoxazol-4-il-imidazo[1,2-a]piridina, metodo de preparacion, medicamentos que los contienen y usos en el tratamiento de trastornos cognitivos.
CY1114702T1 (el) Νεοι εναnτιομερως καθαροι βητα αγωνιστες, μεθοδος για την παραγωγη τους και χρηση αυτων ως φαρμακων
JP2015514073A (ja) スピロ環式ジヒドロ−チアジンおよびジヒドロ−オキサジンbace阻害剤、ならびにその組成物および使用
AU2021262281B2 (en) 1,5-dihydro-2,4-benzodiazepine-3-one derivative and application thereof
JP2006521345A (ja) ニコチン性アセチルコリン受容体の正のアロステリック調節剤
JP2015523406A5 (cg-RX-API-DMAC7.html)
CA3201080A1 (en) 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders
JP2025508323A5 (cg-RX-API-DMAC7.html)
JP2024542881A (ja) Kv7.2阻害剤としての新規ヘテロアリール-尿素化合物
JP2025502712A (ja) シクロプロピル化合物
JP2021506806A (ja) 置換アゼチジンジヒドロチエノピリジンおよびホスホジエステラーゼ阻害剤としてのそれらの使用
JP2025513462A5 (cg-RX-API-DMAC7.html)
JP2019521964A5 (cg-RX-API-DMAC7.html)
JP2024540583A (ja) Kv7.2エンハンサーとしてのピリジン化合物
CA3229358A1 (en) Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto